Determination of hepatitis B virus genotype and detection of lamivudine-resistance mutations;Determinación del genotipo del virus de la hepatitis B y detección de mutaciones de resistencia al tratamiento con lamivudina

Gastroenterologia y Hepatologia

Volumn 27, Issue 9, 2004, Pages 515-520

  Nogales, M C ^a   Serrano, M C ^a   Suarez E ^a   Corpas, R ^a   Perez L ^a   Claro, R ^a   Jarana, R ^a   Romero Gomez M ^a   Martin Mazuelos E ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; DNA HYBRIDIZATION; DNA PROBE; FEMALE; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MUTATIONAL ANALYSIS; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPAIN; TECHNIQUE; VIRUS GENE; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; WILD TYPE;

EID: 9744268914     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13068136     Document Type: Article

References (29)

1. EASL International Consensus Conference on Hepatitis B. J Hepatol 2003;38:533-40.
2. Kidd-Ljunggren K, Miyakawa Y, Kidd AH. Genetic variability in hepatitis B viruses. J Gen Virol 2002;83:1267-80.
3. Arauz-Ruiz P, Norder H, Robertson BH, Magnius L. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002;83:2059-73.
4. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence outcome of HBV infection? J Viral Hepat 1999;6:299-304.
5. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002;123:1848-56.
6. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlates with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000;118:554-9.
7. Yuen MF, Sablon E, Yuan HJ, Wong DKH, Hui CK, Wong BCY, et al. Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications and hepatocellular carcinoma. Hepatology 2003;37:562-7.
8. Zhang X, Zoulim F, Habersetzer F, Xiong S, Trépo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996;48:8-16.
9. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
10. Wai CT, Chu CJ, Hussain M, Lok ASF. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002;36:1425-30.
11. Buti M. Actualización en el tratamiento de la hepatitis crónica B. Gastroenterol Hepatol 2004;27:55-7.
12. Lai CL, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96.
13. Dienstag JL, Goldin RD, Heathcote J, Hann WL, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
14. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
15. Rodríguez-Frías F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995;22:1641-7.
16. Buti M. Genotipos del virus de la hepatitis B. Gastroenterol Hepatol 2003;26:260-2.
17. Kato HK, Orito E, Sugauchi F, Ueda R, Koshizaka T, Yanaka S, et al. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J Virol Methods 2003;110:29-35.
18. Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
19. Rizzetto M. Efficacy of lamivudine in HBeAg negative chronic hepatitis BJM Virol 2002;66:435-41.
20. Si Ahmed SN, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.
21. Lok ASF, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000;32:1145-53.
22. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001;34:584-6.
23. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-91.
24. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998;27:1670-7.
25. Buti M, Cotrina M, Valdés A, Jardi R, Rodríguez- Fiáas F, Esteban R. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002;36:445-6.
26. Zöllner B, Petersen J, Puchhammer-Stöckl E, Kletzmayr J, Sternek M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 2004;39:42-50.
27. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004;39:64-73.
28. Leung NWY, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
29. Chen RYM, Edwards R, Shaw T, Colledge D, Delaney IV WE, Isom H, et al. Effect of the G 1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37:27-35.